Provided by Tiger Trade Technology Pte. Ltd.

Biogen

220.73
+0.84750.39%
Volume:77.76K
Turnover:17.12M
Market Cap:32.59B
PE:39.21
High:221.77
Open:220.00
Low:218.22
Close:219.88
52wk High:230.49
52wk Low:138.00
Shares:147.64M
Float Shares:147.31M
Volume Ratio:0.43
T/O Rate:0.05%
Dividend:- -
Dividend Rate:- -
EPS(TTM):5.63
EPS(LYR):8.79
ROE:4.58%
ROA:5.21%
PB:1.73
PE(LYR):25.11

Loading ...

One Molecule, Three Diseases, $1.55 Billion — Inside CSL's Bet

Bellwether Stocks Movement
·
6 hours ago

Merck Doubled Off Its Lows — And Analysts Still See More Room

Bellwether Stocks Movement
·
7 hours ago

CSL Bets $1.6 Billion on a Drug That Hasn't Finished Phase 2

Bellwether Stocks Movement
·
11 hours ago

Piper Sandler Keeps Their Buy Rating on Biogen (BIIB)

TIPRANKS
·
2 hours ago

Bayer Bets $2.2 Billion That America Is Still The Best Place To Make Drugs

Macro World​
·
Oct 03

23.3% Vs 14.8%: Lilly's New Data Just Changed The Obesity Drug Playbook

Bellwether Stocks Movement
·
Oct 03

Biogen Inc. Stock Underperforms Friday When Compared to Competitors

Dow Jones
·
Oct 03

Biogen Says Litifilimab Safety Profile Consistent with no New Safety Signals Identified

Reuters
·
Oct 03

Biogen's Experimental Lupus Drug Shows Benefit Against Skin Symptoms

Reuters
·
Oct 03

Biogen’s Salanersen Trial Strengthens Its SMA Pipeline Outlook

TIPRANKS
·
Oct 03

Biogen Says Litifilimab Posts Sustained Skin Clearance in 52-Week Phase 2 Cutaneous Lupus Study

Reuters
·
Oct 02

Biogen - 28.8% of Participants Achieve 70% or Greater Reduction in Clasi a at Week 52

THOMSON REUTERS
·
Oct 02

Biogen’s Litifilimab Demonstrates Rapid and Durable Efficacy in New 52-Week Phase 2 Data from Ongoing Phase 2/3 Amethyst Study, Reinforcing Its Potential as a First-in-Class Therapy for Cutaneous Lupus Erythematosus~

THOMSON REUTERS
·
Oct 02

Biogen - Serious Adverse Events Occurred in 3.4% of Participants During 52-Week Treatment Period

THOMSON REUTERS
·
Oct 02

Biogen - 33.7% of Crossover Participants Report Clear or Almost Clear Skin at Week 52

THOMSON REUTERS
·
Oct 02

Novartis Bets $7.8 Billion On MRNA Beyond Vaccines

Options & Short Sell
·
Oct 02

Biogen Inc. Stock Outperforms Competitors Despite Losses on the Day

Dow Jones
·
Oct 02

Compass Pathways Names Kelley Boucher Chief People Officer

Reuters
·
Sep 30

Analysts Conflicted on These Healthcare Names: Harmony Biosciences Holdings (HRMY), BioNTech SE (BNTX) and Biogen (BIIB)

TIPRANKS
·
Sep 26

Pharmaceutical Stocks Jump. Moderna, Eli Lilly up over 3%; Novavax, Pfizer up Around 2%; Merck, Novo Nordisk up over 1%

Tiger Newspress
·
Sep 24